Industry Relations and Technology Transfer
Technologies available from Fred Hutch
- Highlight 1
Muscular Dystrophy (FSHD) Targets
The identification of genes and proteins that damage muscle cells and the mechanisms that cause facioscapulohumeral muscular dystrophy (FSHD), the third most common form of inherited muscular dystrophy, provide opportunities for development of biomarker-based tests to determine risk and diagnose FSHD.
Learn more »
- Highlight 2
- Highlight 3
- Highlight 4
- Highlight 5
- Highlight 6
Fred Hutchinson Cancer Research Center works with industry and investment partners to commercialize its discoveries and maximize their impact on our mission of eliminating cancer and other diseases.
The Industry Relations and Technology Transfer Office serves as the bridge linking companies and investors to the Fred Hutch’s world-class discoveries and scientific faculty.
- Ranks in the top two in National Institutes of Health (NIH) funding among all U.S. independent research institutions
- A leading recipient of National Cancer Institute (NCI) funding among academic and research institutions
- Fiscal year 2012 budget of $419 million
- More than 200 faculty and nearly 600 other scientists working across five scientific divisions
Our approach to these vital partnerships emphasizes relationship-building,
collaboration and shared success.
so we can keep in touch about what's new at the Center and your business and research interests.
Learn about available research tools on our Express Licensing page.
Learn more about our portfolio companies and other partnerships on our Success Stories page.
Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect
and treat cancer and other life-threatening diseases.